Uneingeschränkter Zugang

Prevalence of Closely Related Candida albicans Species among Patients with Vulvovaginal Candidiasis in Southern Poland Based on the hwp1 Gene Amplification


Zitieren

Fig. 1.

Morphology of reference strains of yeasts colonies after 48 h incubation in 37°C on chromID® Candida (bioMérieux, France).
A. a) Candida albicans ATCC® 90028™ (dark blue colonies), b) Candida glabrata ATCC® 2001™ (white colonies), c) Candida tropicalis ATCC® 9968™ (pink colonies).
B. a) Candida africana ATCC® MYA 2669™ (small, light blue colonies), b) Candida albicans ATCC® 90028™ (dark blue colonies), c) Candida dubliniensis clinical strain (turquoise colonies).
Morphology of reference strains of yeasts colonies after 48 h incubation in 37°C on chromID® Candida (bioMérieux, France). A. a) Candida albicans ATCC® 90028™ (dark blue colonies), b) Candida glabrata ATCC® 2001™ (white colonies), c) Candida tropicalis ATCC® 9968™ (pink colonies). B. a) Candida africana ATCC® MYA 2669™ (small, light blue colonies), b) Candida albicans ATCC® 90028™ (dark blue colonies), c) Candida dubliniensis clinical strain (turquoise colonies).

Fig. 2.

Representative samples of the hwp1 gene PCR assay visualised in electrophoresis.
Line 1 and 13 – molecular weight marker (O’GeneRuler 50 bp DNA Ladder; Thermo Scientific, USA)
Line 2 – positive control of Candida albicans ATCC® 90028™ (product size 941 bp). Line 3 – positive control of Candida dubliniensis NCPF 3949 (product size 569 bp). Line 4 – positive control of Candida africana ATCC® MYA 2669™ (product size 700 bp)
Line 5, 6, 7, 9, 11 – clinical Candida albicans strains. Line 8, 10 – clinical Candida dubliniensis strains. Line 12 – negative control
Representative samples of the hwp1 gene PCR assay visualised in electrophoresis. Line 1 and 13 – molecular weight marker (O’GeneRuler 50 bp DNA Ladder; Thermo Scientific, USA) Line 2 – positive control of Candida albicans ATCC® 90028™ (product size 941 bp). Line 3 – positive control of Candida dubliniensis NCPF 3949 (product size 569 bp). Line 4 – positive control of Candida africana ATCC® MYA 2669™ (product size 700 bp) Line 5, 6, 7, 9, 11 – clinical Candida albicans strains. Line 8, 10 – clinical Candida dubliniensis strains. Line 12 – negative control

Fig. 3.

Susceptibility of 309 Candida albicans clinical isolates caused VVC obtained by Fungitest™ (BioRad, France).
S – susceptible, I – intermediate (referring to “susceptible, increased exposure” according to the EUCAST recommendations), R – resistant.
Susceptibility of 309 Candida albicans clinical isolates caused VVC obtained by Fungitest™ (BioRad, France). S – susceptible, I – intermediate (referring to “susceptible, increased exposure” according to the EUCAST recommendations), R – resistant.

Percentage of compatible results obtained by the methods used to discriminate species among Candida albicans complex (VITEK®2 system and MALDI-TOF MS) with the hwp1 gene amplification with PCR.

The compliance with PCR assayNo. (%) n = 326
VITEK 2 319 (97.85) 7 (2.15)
MALDI-TOF MS 323 (99.08) 3 (0.92)

Molecular discrimination among Candida albicans complex.

Species No. (%) n = 326
Candida albicans 307 (94.17)
Candida dubliniensis 17 (5.21)
Candida albicans + Candida dubliniensis 2 (0.61)

Discrepancies between species identification among Candida albicans complex obtained by the Vitek®2 system, MALDI-TOF MS and the hwp1 gene amplification with PCR.

Isolate No. VITEK 2 MALDI-TOF MS PCR assay based on the hwp1 gene amplification
Species identification Confidence level (probability) Species identification Confidence level Species identification Product size (bp)
CA67 clinical strain Candida albicans/Candida dubliniensis low (< 85%) Candida dubliniensis 99.90% Candida dubliniensis 569
CA95 clinical strain Candida albicans excellent (96%) Candida albicans 99.90% Candida albicans + Candida dubliniensis 941 + 569
CA98 clinical strain not identified Candida dubliniensis 99.90% Candida dubliniensis 569
CA125 clinical strain Candida ciferrii acceptable (86%) Candida dubliniensis 99.90% Candida dubliniensis 569
CA13 clinical strain Candida albicans/Candida dubliniensis low (< 85%) Candida dubliniensis 99.90% Candida dubliniensis 569
CA137 clinical strain Candida albicans good (91%) Candida albicans 99.90% Candida dubliniensis 569
CA313 clinical strain Candida albicans very good (95%) Candida albicans 99.90% Candida albicans + Candida dubliniensis 941 + 569
Candida albicansATCC® 90028™ reference strain Candida albicans excellent (98%) Candida albicans 99.90% Candida albicans 941
Candida dubliniensisNCPF 3949 reference strain Candida dubliniensis very good (93%) Candida dubliniensis 99.90% Candida dubliniensis 569
Candida africanaMYA 2669™ reference strain Candida dubliniensis/Candida parapsilosis low (< 85%) Candida albicans 99.90% Candida africana 700

Prevalence of single VVC and co-occurrence with bacteria.

Type of co-occurrence No. (%)n = 326
Single VVC 197 (60.43)
VVC + bacteria: 129 (39.57)
  Gardnerella vaginalis   60 (18.40)
  Streptococcus agalactiae   41 (12.58)
  Gardnerella vaginalis + Streptococcus agalactiae    11 (3.37)
  Escherichia coli      9 (2.76)
  Escherichia coli + Streptococcus agalactiae      3 (0.92)
  Gardnerella vaginalis + Escherichia coli      2 (0.61)
  Methicillin susceptible Staphylococcus aureus      1 (0.31)
  Streptococcus pyogenes      1 (0.31)
  Klebsiella pneumoniae + Streptococcus agalactiae      1 (0.31)
eISSN:
2544-4646
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Biologie, Mikrobiologie und Virologie